Abstract
Despite advances in supportive care and medical technology, the mortality rate from sepsis remains high (35–50%) (1). It is the most common cause of death in non-cardiac intensive care units, and the incidence appears to be rising (2). Over the last 20 years, prevailing thought has attributed much of the morbidity and mortality of sepsis to an overexuberant host inflammatory response to bacteria or bacterial products. In preclinical studies, agents designed to limit this host pro-inflammatory response showed promising effects, prompting numerous clinical trials.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Wheeler, AP, and GR. Bernard. Treating patients with severe sepsis. N Eng J Med 1999;340:207–214.
Linde-Swirbe, WT, DC. Angus, J. Carcillo, et al. Age specific incidence and outcome of sepsis in the US. Crit Care Med 1999;27:A33.
Hartman, F. A., and W. J. M. Scott. Protection of adrenalectomized animals against bacterial intoxication by an extract of the adrenal cortex. J Exp Med 1932;55:63–69.
Sacks, M. S. Fulminating septicemia associated with purpura and bilateral adrenal hemorrhage (Waterhouse-Friderichsen Syndrome); report of two cases with review of the literature. Ann Int Med 1936:1105–1114.
Hinshaw, L. B., L. T. Archer, and B. K. Beller-Todd. Survival of primates in LD100 septic shock following steroid/antibiotic therapy. J Surg Res 1980;28:151–170.
Fabian, T. C., and R. Patterson. Steroid therapy in septic shock. Survival study in a laboratory model. Am Surgeon 1982;48:614–617.
Hinshaw, L. B., B. K. Beller-Todd, L. T. Archer, et al. Effectiveness of steroid antibiotic treatment in primates administered LD100 Eschericia coli. Ann Surg 1981;194:51–56.
Hinshaw, L. B., D. J. Flournoy, L. T. Archer, et al. Recovery from lethal Escherichia coli shock. Surg Gyn Ob 1979; 149:545–553.
White, G. L., L. T. Archer, B. K. Beller-Todd, et al. Increased survival with methylprednisolone treatment in canine endotoxin shock. J Surg Res 1978;25.
Beller-Todd, B. K. L. T. Archer, R. Passey, et al. Effectiveness of modified steroid-antibiotic therapies for lethal sepsis in the dog. Arch Surg 1983;118:1293–1299.
Bennett, I. L., M. Finland, M. Hamborger, et al. The effectiveness of hydrocortisone in the management of severe infection. JAMA 1963;183:462–465.
Luce, J. M., A. B. Montgomery, J. D. Marks, et al. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 1988;138:62–68.
The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987;317:653–658.
Bone, R., C. Fisher, T. Clemmer, et al. A controlled trial of high dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653–658.
Sprung, C., P. Caralis, E. Marcial, et al. The effects of high dose corticosteroids in patients with septic shock. N Eng J Med 1984;311:1137–1143.
Thompson, W. L, H. T. Gurley, B. A. Lutz, et al. Inefficacy of glucocorticoids in shock (double-blind study). Clin Res 1976;24:258A.
Schumer, W. Steroids in the treatment of clinical shock. Ann Surg 1976;184:133–139.
Klastersky, J., R. Cappell, and L. Debusscher. Effectiveness of betamethasone in management of severe infections. N Eng J Med 1971;284:1248–1250.
Cronin, L., D. J. Cook, and J. Carlet. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1997;23:1430–1439.
Lefering, R., and E. A. Neugebauer. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995;23:1294–1303.
Zeni, F., B. Freeman, and C. Natanson. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 1997;25:1095–1100.
Schumer, W. Steroid in the treament of clinical septic shock. Arch Surg 1976;184: 537–541.
The Veterans Association Systemic Sepsis Cooperative Study Group. Effect of high dose glucocorticoid therapy on mortality in patients with clinical signs of sepsis. N Engl J Med 1987;317:653–658.
Meduri, G., and G. Chrousos. Duration of glucocorticoid treatment and outcome in sepsis. Chest 1998;114:355–359.
Bollaert, P.-E., C. Charpentier, B. Levy, et al. Reversal of late septic shock in with supraphysiologic doses of hydrocortisone. Crit Care Med 1998;26:645–650.
Briegel, J., H. Forst, M. Hallar, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single center study. Crit Care Med 1999;27:723–732.
Chawla, K., Y. Kupfer, I. Goldman, et al. Hydrocortisone reverses refractory septic shock. Crit Care Med 1999;27:A33.
ACCP SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine 1992;20:864–874.
Abraham, E., R. Wunderink, H. Silverman, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis syndrome. A randomized, controlled, double-blind multi-center clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995;273:934–941.
Cohen, J., and J. Carlet. Intersept: An international, multicenter, placebo controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. Crit Care Med 1996;24:1431–1440.
Abraham, E., A. Anzueto, G. Guterrez, et al. Double-blind randomized controlled trial of monoclonal antibody to human tumor necrosis factor in human septic shock. Lancet 1998;351:929–933.
Clark, M., L. Plank, A. Connolly, et al. Effect of a chimeric antibody to tumor necrosis factor alpha on cytokine and physiologic responses in patients with severe sepsis. A randomized clinical trial. Crit Care Med 1998;26:1650–1659.
Rheinhart, K., C. Wiegland-Lohnart, F. Grimmanger, et al. Assessment of the safety and efficacy of the monoclonal antitumor necrosis factor antibody-fragment MAK 19F in patients with sepsis and septic shock: a multicenter, randomized placebo-controlled study. Crit Care Med 1996;24:733–742.
Kay, C. A. Can better measures of cytokine responses be obtained to guide cytokine inhibition? Pressentation and handout Washington DC, Cambridge Health Institutes February 20-1, 1996.
Dhainaut, J., J. Vincent, C. Richard, et al. CD571, a humanized antibody to tumor necrosis factor-alpha: safety, pharmacodynamics, immune responses and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 1995;21:1461–1469.
Fisher, C., S. Opal, J. Dhainaut, et al. The CB006 Sepsis Syndrome Study Group. Crit Care Med 1993;21:318–327.
Abraham, E., M. Glauser, T. Butler, et al. P55 tumor nerosis factor receptor fusion protein in the treatment of patients with septic shock. JAMA 1997;277:1531–1538.
Abraham, E. Immunomodulatory therapy in sepsis: failure in clinical trials or critical thinking. International Conference, American Thoracic Society, Chicago, Illinois Tuesday April 28, 1998.
Fisher, C., J. Agosti, S. Opal, et al. Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein. N Engl J Med 1997;334:1697–1702.
Fisher, C., G. Slotman, S. Opal, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open label, placebo controlled clinical trial. Crit Care Med 1994;22:12–21.
Opal, S., C. Fisher, F. Dhainaut, et al. Confirmatory interleuken-1 receptor antagonist in severe sepsis: a phase III, randomized double-blind, placebo controlled,multi-center trial. Crit Care Med 1997;25:1115–1124.
Fisher, C., J. Dhainaut, and S. Opal. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with the sepsis syndrome. JAMA 1994;271:1836–1848.
Dhainaut, J., A. Tenaillon, Y. deTulzo, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: A randomized, placebo controlled, multi-center clinical trial. Crit Care Med 1994;22:1720–1728.
Dhainaut, J., A. Tenaillon, M. Hemmer, et al. The confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram negative bacterial sepsis: a multi-center, randomized, placebo controlled, multicenter trial. Crit Care Med 1998;26:1963–1971.
Rodell, T., and C. Foster. Sepsis data show negative trend in second phase II sepsis trial. Press Release. Cortec, Inc, 7000 North Broadway, Denver CO 80821 July 18, 1995.
Fein, A., G. Bernard, G. Criner, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127): results of a randomized, double-blind, placebo controlled trial. JAMA 1997;277:482–487.
Jacobs, E., M. Soulsby, R. Bone, et al. Ibuprofen in canine endotoxin shock. J Clin Invest 1982;70:536–571.
Wright, P. E., and G. R. Bernard. Mechanisms of late hemodynamic and airway dynamic responses to endotoxin in awake sheep. Am Rev Resp Dis 1989;140:672–678.
Bernard, G., A. Wheeler, J. Rüssel, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The ibuprofen in sepsis study group. N Engl J Med 1997;336:912–918.
Haupt, M., M. Jastremski, T. Clemmer, et al. Effect of ibuprofen in patients with severe sepsis; a randomized, double-blind multi-center trial. Crit Care Med 1991;19:1339–1347.
Sevransky, J. E., and C. Natanson. An analysis of clinical trials of mediator-specific anti-inflammatory agents. Sepsis 1999;3:11–19.
Natanson, C., C. Esposito, and S. M. Banks. The siren’s song of confirmatory sepsis trials; selection bias and sampling error. Crit Care Med 1998;26:1927–1931.
Natanson, C., P. W. Eichenholz, and R. L. Danner. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989; 169:823–832.
Suffredini, A. F., R. E. Fromm, M. M. Parker, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280–287.
Natanson, H. W., Suffredini AF, Eichacker PQ, and Danner RL. Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis. Ann Int Med 1994;120:771–783.
Ziegler, E. J., J. A. McCutchan, and J. Fierer. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Esherichia coli. N Engl J Med 1982;307:1225–1230.
Ziegler, E. J., C. J. Fisher, and C. L. Sprung. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. New Engl J Med 1991;324:429–436.
The J5 Study Group. Treatment of severe infectious purpura in children with human plasma from donors immunized with Esherichia coli J5: a prospective double-blind study. J Infect Dis 1992; 165:695–701.
Calandra, T., M. P. Glauser, J. Schellekens, et al. Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5; a prospective, double-blind, randomized trial. J Infect Dis 1988;158:312–319.
Greenman, R. L., R. M. H. Scein, and M. A. Martin. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 1991;266:1097–1102.
Bone, R. C., R. A. Balk, and A. M. Fein. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995;23:994–1006.
McClosky, R. V., R. C. Straube, C. Sanders, et al. Treatment of septic shock with human monoclonal antibody HA-1A. Ann Int Med 121: 1–5, 1994.
McCutchan, J. A., J. L. Wolf, E. L. Ziegler, et al. Ineffectiveness of single-dose human antiserum to core glycolipid (Esherichia coli J5) for prophylaxis of bacteremic, gramnegative infection in patients with prolonged neutropenia. J Suisse de Medecine 1983;113(s):40–55.
The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin compared with corelipopolysaccaride immune globulin in patients at high risk of post-surgical infection. N Engl J Med 1992;327:234–240.
Baumgartner, J. D., D. Heumann, J. Gerain, et al. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies. J Exp Med 1990; 171:889–896.
Baumgartner, J. D. Immunotherapy with antibodies to core lipopolysaccharide: a critical appraisal. Infect Dis Clinics NA 1991;5:915–917.
Aiki, H., M. Kodama, T. Tani, et al. Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surgery 1994;167:412–4171994.
Bernard GR, Reines HD, Haluska DV. Prostacyclin and thromboxone A2 formatica is increased in human sepsis syndrome: effects of cyclooxygenase inhibition. Am Rev Respir Dis 1991;144:1095–1101.
Lucas CE, Ledgerwood AN. The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg 1984;119:537–541.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sevransky, J., Natanson, C. (2001). Anti-Inflammatory Therapy in Sepsis. In: Eichacker, P.Q., Pugin, J. (eds) Evolving Concepts in Sepsis and Septic Shock. Perspectives on Critical Care Infectious Diseases, vol 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1581-4_9
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1581-4_9
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5625-7
Online ISBN: 978-1-4615-1581-4
eBook Packages: Springer Book Archive